ASCENTAGE PHARMA GROUP INTERNATIONAL
AAPGDrugs in Pipeline
17
Phase 3 Programs
8
Upcoming Catalysts
3
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
3 upcoming, 3 past
Olverembatinib
GIST
APG-2575(Lisaftoclax )
Acute Myeloid Leukemia
Acalabrutinib
CLL/SLL
Imatinib
Ph+ ALL
Bosutinib
Chronic Myeloid Leukemia
lisaftoclax +BTK inhibitor
CLL/SLL
Lisaftoclax (APG-2575)
Relapsed/Refractory Acute Myeloid Leukaemia
Azacitidine Injection
Higher-risk Myelodysplastic Syndrome
Ibrutinib
Chronic Lymphocytic Leukemia
APG2575
Chronic Lymphocytic Leukemia
APG-115
AML
APG-1252
NHL, Adult
Phase 1b: APG-115+pembrolizumab
Unresectable or Metastatic Melanoma or Advanced Solid Tumors
HQP1351
Chronic Myeloid Leukemia, Chronic Phase
APG-1387 for Injection
Advanced Pancreatic Cancer
Toripalimab
Liposarcoma
APG-2575
T-Prolymphocytic Leukemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Olverembatinib | Phase 3 | GIST | - | - |
APG-2575(Lisaftoclax ) | Phase 3 | Acute Myeloid Leukemia | - | - |
Acalabrutinib | Phase 3 | CLL/SLL | - | - |
Imatinib | Phase 3 | Ph+ ALL | - | - |
Bosutinib | Phase 3 | Chronic Myeloid Leukemia | - | - |
lisaftoclax +BTK inhibitor | Phase 3 | CLL/SLL | - | - |
Lisaftoclax (APG-2575) | Phase 3 | Relapsed/Refractory Acute Myeloid Leukaemia | - | - |
Azacitidine Injection | Phase 3 | Higher-risk Myelodysplastic Syndrome | - | - |
Ibrutinib | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
APG2575 | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
APG-115 | Phase 2 | AML | - | - |
APG-1252 | Phase 2 | NHL, Adult | - | - |
Phase 1b: APG-115+pembrolizumab | Phase 2 | Unresectable or Metastatic Melanoma or Advanced Solid Tumors | - | - |
HQP1351 | Phase 2 | Chronic Myeloid Leukemia, Chronic Phase | - | - |
APG-1387 for Injection | Phase 2 | Advanced Pancreatic Cancer | - | - |
Toripalimab | Phase 2 | Liposarcoma | - | - |
APG-2575 | Phase 2 | T-Prolymphocytic Leukemia | - | - |